Maleeruk UtsintongPiyanuch RojsangaKwok Yiu HoTodd T. TalleyArthur J. OlsonKinzo MatsumotoOpa VajraguptaUniversity of PhayaoMahidol UniversityUniversity of California, San DiegoScripps Research InstituteUniversity of Toyama2018-06-112018-06-112012-02-01Journal of Biomolecular Screening. Vol.17, No.2 (2012), 204-2151552454X108705712-s2.0-84856300928https://repository.li.mahidol.ac.th/handle/20.500.14594/13816The nicotinic acetylcholine receptors (nAChRs) are a member of the ligand-gated ion channel family and play a key role in the transfer of information across neurological networks. The X-ray crystal structure of agonist-bound α7 acetylcholine binding protein (AChBP) has been recognized as the most appropriate template to model the ligand-binding domain of nAChR for studying the molecular mechanism of the receptor-ligand interactions. Virtual screening of the National Cancer Institute diversity set, a library of 1990 compounds with nonredundant pharmacophore profiles, using AutoDock against AChBPs revealed 51 potential candidates. In vitro radioligand competition assays using [3H] epibatidine against the AChBPs from the freshwater snails, Lymnaea stagnalis, and from the marine species, Aplysia californica and the mutant (AcY55W), revealed seven compounds from the list of candidates that had micromolar to nanomolar affinities for the AChBPs. Further investigation on α7nAChR expressing in Xenopus oocytes and on the recombinant receptors with fluorescence resonance energy transfer (FRET)-based calcium sensor expressing in HEK cells showed that seven compounds were antagonists of α7nAChR, only one compound (NSC34352) demonstrated partial agonistic effect at low dose (10 μM), and two compounds (NSC36369 and NSC34352) were selective antagonists on α7nAchR with moderate potency. These hits serve as novel templates/scaffolds for development of more potent and specific in the AChR systems. © 2012 Society for Laboratory Automation and Screening.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyChemistryPharmacology, Toxicology and PharmaceuticsVirtual screening against acetylcholine binding proteinArticleSCOPUS10.1177/1087057111421667